Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Dr. Ingmar Gorman is a co-founder of Fluence and a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. Dr. Gorman is a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.
Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psilocybin-Assisted treatment of Major Depressive Disorder, a collaborator with Yale University’s study on psilocybin-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS study on treatment of Post Traumatic Stress Disorder with MDMA-Assisted Psychotherapy. Jeff is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He co-authored a paper on the influence of therapists’ first hand experience with psychedelics on psychedelic-assisted psychotherapy research in The Journal of Psychedelic Studies. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies. He maintains a private practice in New York City.
No. Our trainings do not include any administration of any psychedelic compounds. While we recognize that such experiences can be a valuable part of training for some professionals in certain situations, we believe they are neither necessary nor sufficient, and value a more general familiarity with alternative states of consciousness.
Depending on the compound there may be a legal avenue to do so either by participating in a research trial, receiving treatment (as a patient) with a currently available psychedelic (e.g. ketamine), or traveling abroad.
Some of our programs offer the option to purchase APA CE and/or CME certificate. You will need to check with your licensing board in your state to see if those credits are acceptable for your purposes.
Our intention is to keep our fees affordable for working mental health professionals. At most of our programs we reserve select number of spaces for a discounted rate for applicants whose presence would benefit the community for whom our fee would be a hardship. We prioritize providing scholarships to participants whose participation will enhance diversity among clinicians educated in this modality and/or the populations to which it is available. Applications will be accepted and scholarships awarded on a rolling basis, so please apply early. Where available, you will find a link to the application for a scholarship spot on the page for each training. Please note scholarships only apply to training fees and do not cover transportation, lodging, and meals.
We work with a variety of community partners to bring our trainings to their hometowns. Our programs can be open to the public or private for the members of your organization, and tailored to suit your community’s needs. If you would like to collaborate on holding a training locally, please email us and we’ll start the conversation.
At this time we are not accepting clients for psychedelic integration psychotherapy. If you are seeking a therapist who is trained in this area, please contact the Psychedelic Education & Continuing Care Program or search the therapist listings at psychedelic.support. Additionally you may find this guide to finding a therapist for psychedelic integration helpful.